glutamate

glutamate

title: Glutamate
description: Page for Glutamate
published: true
tags: kind:entity, section:entities, state:published, evidence:strong
editor: markdown
pageId: 995
dateCreated: "2026-02-27T00:41:39.616Z"
dateUpdated: "2026-03-24T01:06:20.219Z"
refs:
meldrum2000:
authors: '[Meldrum BS'
title: 'Glutamate as a neurotransmitter in the brain: review of physiology and pathology'
journal: J Nutr
year: 2000
doi: 10.1093/jn/130.4.1007S
dong2009:
title: Dong XX, Wang Y, Bhatt AB. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009;30(4):379-387. DOI
year: 2009
doi: 10.1007/s00401-009-0495-z
danbolt2001:
authors: '[Danbolt NC'
title: Glutamate uptake
journal: Prog Neurobiol
year: 2001
doi: 10.1016/S0301-0082(01
bhatt2023:
title: 'Bhatt DK, Rojas-Perez E, Bhatt R. Glutamate and excitotoxicity in central nervous system disorders: ionotropic glutamate receptors as a target for neuroprotection. Neuroprotection. 2023;2(1):e46.
[DOI'
year: 2023
doi: 10.1002/nep3.46
li2011:
authors: Li S, Hong S, Bhatt DK, et al. Soluble oligomers of
title: amyloid-beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. J Neurosci. 2011;31(16):6233-6246. DOI
year: 2011
doi: 10.1523/JNEUROSCI.6542-10.2011
litim2017:
authors: Litim N, Bhatt AB, Bhatt DK. Metabotropic glutamate receptors as therapeutic targets in
title: ''parkinsons: an update.

...

glutamate

title: Glutamate
description: Page for Glutamate
published: true
tags: kind:entity, section:entities, state:published, evidence:strong
editor: markdown
pageId: 995
dateCreated: "2026-02-27T00:41:39.616Z"
dateUpdated: "2026-03-24T01:06:20.219Z"
refs:
meldrum2000:
authors: '[Meldrum BS'
title: 'Glutamate as a neurotransmitter in the brain: review of physiology and pathology'
journal: J Nutr
year: 2000
doi: 10.1093/jn/130.4.1007S
dong2009:
title: Dong XX, Wang Y, Bhatt AB. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009;30(4):379-387. DOI
year: 2009
doi: 10.1007/s00401-009-0495-z
danbolt2001:
authors: '[Danbolt NC'
title: Glutamate uptake
journal: Prog Neurobiol
year: 2001
doi: 10.1016/S0301-0082(01
bhatt2023:
title: 'Bhatt DK, Rojas-Perez E, Bhatt R. Glutamate and excitotoxicity in central nervous system disorders: ionotropic glutamate receptors as a target for neuroprotection. Neuroprotection. 2023;2(1):e46.
[DOI'
year: 2023
doi: 10.1002/nep3.46
li2011:
authors: Li S, Hong S, Bhatt DK, et al. Soluble oligomers of
title: amyloid-beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. J Neurosci. 2011;31(16):6233-6246. DOI
year: 2011
doi: 10.1523/JNEUROSCI.6542-10.2011
litim2017:
authors: Litim N, Bhatt AB, Bhatt DK. Metabotropic glutamate receptors as therapeutic targets in
title: ''parkinsons: an update. Neuropharmacology. 2017;115:166-179. DOI''
year: 2017
doi: 10.1016/j.neuropharm.2016.10.001
rothstein1995:
title: Rothstein JD, Van Kammen M, Bhatt DK. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol. 1995;38(1):73-84. DOI
year: 1995
doi: 10.1002/ana.410380314
bensimon1994:
title: Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330(9):585-591. DOI
year: 1994
doi: 10.1056/NEJM199403033300901
zeron2002:
authors: Zeron MM, Bhatt DK, Bhatt R, et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's Disease. *
title: neurons*. 2002;33(6):849-860. DOI
year: 2002
doi: 10.1038/nn734
rothstein2005:
authors: Rothstein JD, Patel S, Bhatt DK, et al.
title: β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433(7021):73-77. DOI
year: 2005
doi: 10.1038/nature03180
zhou2025:
title: Zhou Y, Bhatt DK, Bhatt R. Bhatt Bhatt — update on glutamate excitotoxicity molecular mechanisms in neurodegeneration. Acta Pharmacol Sin. 2025. DOI
year: 2025
doi: 10.1038/s41401-025-01576-w
nguyen2025:
authors: Nguyen H, Bhatt DK, et al.
title: Multi-omic analysis of glutamate excitotoxicity in primary neuronal cultures. J Neurochem. 2025;169(1):e70110. DOI
year: 2025
doi: 10.1111/jnc.70110
lewerenz2015:
title: Lewerenz J, Maher P. Chronic glutamate toxicity in neurodegenerative diseases — what is the evidence? Front Neurosci. 2015;9:469. DOI
year: 2015
doi: 10.3389/fnins.2015.00469
neurodegenerative:
title: ''- Neurodegenerative Diseases''
genes:
title: ''- Genes Index''
mechanisms:
title: ''- Mechanisms of Neurodegeneration''
proteins:
title: ''- Proteins Index## See Also''
neurodegenerativea:
title: ''- Neurodegenerative Diseases''
mechanismsa:
title: ''- Mechanisms Index## External Links''
ncbi:
authors: '-'
title: NCBI Gene
url: https://www.ncbi.nlm.nih.gov/gene/
uniprot:
authors: '-'
title: UniProt
url: https://www.uniprot.org/
ref:
title: '-'
url: https://pubmed.ncbi.nlm.nih.gov/

Glutamate

Introduction

Glutamate is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Glutamate is the principal excitatory neurotransmitter in the mammalian central nervous system, mediating the vast majority of fast excitatory synaptic transmission. Present in over 90% of all excitatory synapses, glutamate plays essential roles in [long-term-potentiation](/mechanisms/long-term-potentiation), learning, memory, and neural development. However, excessive glutamate signaling — a process termed excitotoxicity — is a major pathological mechanism contributing to neuronal death in virtually all neurodegenerative diseases, including [alzheimers](/diseases/alzheimers-disease), [parkinsons](/diseases/parkinsons-disease), [als](/diseases/amyotrophic-lateral-sclerosis), [huntington-pathway](/mechanisms/huntington-pathway), and [multiple-sclerosis](/diseases/multiple-sclerosis) ([Meldrum, 2000](https://doi.org/10.1093/jn/130.4.1007S); [Dong et al., 2009](https://doi.org/10.1007/s00401-009-0495-z)). [@dong2009]

Glutamate signaling operates through a complex system of ionotropic and metabotropic receptors, high-affinity transporters, and metabolic enzymes. Disruption of any component of this signaling system can shift the balance from physiological neurotransmission to pathological [excitotoxicity](/mechanisms/excitotoxicity), making glutamatergic dysfunction a central therapeutic target in neurodegeneration. [@danbolt2001]

Glutamate Synthesis and Metabolism

Glutamate-Glutamine Cycle

Glutamate homeostasis is maintained by the glutamate-glutamine cycle between [neurons](/entities/neurons) and [astrocytes](/cell-types/astrocytes): [@bhatt2023]

Release: Glutamate is released from presynaptic vesicles into the synaptic cleft upon neuronal depolarization

Uptake: [astrocytes](/cell-types/astrocytes) rapidly clear synaptic glutamate via excitatory amino acid transporters (EAATs), primarily EAAT1 (GLAST) and EAAT2 (GLT-1), which account for approximately 90% of glutamate reuptake ([Danbolt, 2001](https://doi.org/10.1016/S0301-0082(01)00067-8))

Conversion: In [astrocytes](/cell-types/astrocytes), glutamine synthetase converts glutamate to glutamine

Recycling: Glutamine is released and taken up by [neurons](/entities/neurons), where glutaminase reconverts it to glutamate for repackaging into synaptic vesicles

Biosynthesis

Glutamate is synthesized through multiple pathways: [@li2011]

• From glutamine: Via mitochondrial glutaminase (the primary synaptic source)
• From α-ketoglutarate: Via aspartate aminotransferase (linking the TCA cycle to neurotransmission)
• From [gaba](/entities/gaba): Via GABA-transaminase (connecting excitatory and inhibitory neurotransmission)
• De novo synthesis: Via pyruvate carboxylase in [astrocytes](/cell-types/astrocytes) (the only CNS cell type capable of net glutamate synthesis)

Glutamate Receptors

Ionotropic Receptors

Ionotropic glutamate receptors (iGluRs) are ligand-gated ion channels that mediate fast excitatory transmission: [@litim2017]

NMDA Receptors

[nmda-receptor](/entities/nmda-receptor) receptor] receptor] receptors] (N-methyl-D-aspartate) are heterotetrameric channels composed of obligatory GluN1 subunits combined with GluN2A-D or GluN3A-B subunits. Key features include: [@rothstein1995]

• Voltage-dependent Mg²⁺ block: At resting potential, Mg²⁺ ions block the channel pore, requiring prior membrane depolarization for activation — making NMDARs coincidence detectors for presynaptic and postsynaptic activity
• Ca²⁺ permeability: High permeability to calcium makes NMDARs critical for both synaptic plasticity and excitotoxic neuronal death
• Co-agonist requirement: Glycine or D-serine binding to the GluN1 subunit is required for channel opening
• Slow kinetics: Prolonged channel opening and calcium influx compared to AMPA/kainate receptors

[nmda-receptor](/entities/nmda-receptor) receptor] receptor] receptor overactivation is the primary mediator of excitotoxic neuronal death. Excessive Ca²⁺ influx through NMDARs activates [calpains](/entities/calpains), neuronal nitric oxide synthase (nNOS), and mitochondrial dysfunction cascades ([Bhatt et al., 2023](https://doi.org/10.1002/nep3.46)). [@bensimon1994]

AMPA Receptors

AMPA receptors (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) mediate the majority of fast excitatory transmission. Composed of GluA1-4 subunits, they are permeable primarily to Na⁺ and K⁺. GluA2-lacking AMPA receptors are also Ca²⁺-permeable and implicated in excitotoxicity. AMPA receptor trafficking (insertion and removal from the synapse) is a key mechanism underlying [long-term-potentiation](/mechanisms/long-term-potentiation) and dendritic spine remodeling. [@zeron2002]

Kainate Receptors

Composed of GluK1-5 subunits, kainate receptors modulate both excitatory and inhibitory transmission. They play roles in presynaptic modulation of neurotransmitter release, postsynaptic depolarization, and neuronal excitability regulation. Kainate receptors are implicated in epileptogenesis and may contribute to excitotoxicity. [@rothstein2005]

Metabotropic Receptors

Metabotropic glutamate receptors (mGluRs) are G-protein-coupled receptors divided into three groups: [@zhou2025]

• Group I (mGluR1, mGluR5): Coupled to Gq; activate phospholipase C, increase intracellular Ca²⁺ via IP3 receptors, and enhance NMDAR currents. mGluR5 activation amplifies excitotoxicity and is a therapeutic target in several neurodegenerative diseases
• Group II (mGluR2, mGluR3): Coupled to Gi/Go; inhibit adenylyl cyclase and reduce glutamate release. mGluR2/3 agonists are neuroprotective by limiting excessive glutamate signaling
• Group III (mGluR4, mGluR6, mGluR7, mGluR8): Coupled to Gi/Go; presynaptic autoreceptors that reduce glutamate release

Excitotoxicity: Mechanisms of Glutamate-Mediated Neuronal Death

[excitotoxicity](/mechanisms/excitotoxicity) is the process by which excessive glutamate receptor activation leads to neuronal injury and death. The excitotoxic cascade involves: [@nguyen2025]

Calcium Overload

Excessive [nmda-receptor](/entities/nmda-receptor) receptor] receptor] receptor] activation causes massive Ca²⁺ influx, overwhelming intracellular calcium buffering capacity. Elevated cytoplasmic calcium activates destructive enzymes: [@lewerenz2015]

• [calpains](/entities/calpains): Ca²⁺-dependent proteases that degrade cytoskeletal proteins, signaling molecules, and ion channels
• Phospholipases: Break down membrane phospholipids, generating [oxidative-stress](/mechanisms/oxidative-stress) ([oxidative-stress](/mechanisms/oxidative-stress) and inflammatory mediators (arachidonic acid)
• Endonucleases: Activate DNA fragmentation pathways
• Nitric oxide synthase (nNOS): Produces excessive nitric oxide (NO), which reacts with superoxide to form the highly toxic peroxynitrite (ONOO⁻)

Mitochondrial Dysfunction

Excessive Ca²⁺ is taken up by [mitochondrial-dynamics](/entities/mitochondrial-dynamics) via the mitochondrial calcium uniporter, leading to: [@neurodegenerative]

• Opening of the mitochondrial permeability transition pore (mPTP)
• Collapse of the mitochondrial membrane potential
• Release of cytochrome c, triggering apoptotic cascades
• Impaired ATP production and energy failure
• Generation of [oxidative-stress](/mechanisms/oxidative-stress) from dysfunctional electron transport chain complexes
• Release of [apoptosis](/mechanisms/apoptosis)-inducing factor (AIF), contributing to caspase-independent cell death ([Bhatt et al., 2023](https://doi.org/10.1002/nep3.46))

Oxidative Stress

Excitotoxicity generates massive [oxidative-stress](/mechanisms/oxidative-stress) through: [@genes]

• Mitochondrial [oxidative-stress](/mechanisms/oxidative-stress) production from Ca²⁺-overloaded mitochondria
• NADPH oxidase activation
• Xanthine oxidase activation
• Peroxynitrite formation from NO and superoxide
• Disruption of glutathione antioxidant defense systems

Downstream Death Pathways

Excitotoxicity can trigger multiple cell death pathways: [@mechanisms]

• [apoptosis](/mechanisms/apoptosis): Caspase-dependent programmed cell death via mitochondrial cytochrome c release
• Necrosis: Rapid, uncontrolled cell death from energy failure and membrane disruption
• [necroptosis](/mechanisms/necroptosis): Programmed necrosis mediated by RIPK1/RIPK3/MLKL
• [ferroptosis](/mechanisms/ferroptosis): Iron-dependent lipid peroxidation, increasingly linked to glutamate-induced toxicity through cystine/glutamate antiporter (system Xc⁻) inhibition
• Parthanatos: PARP-1-dependent cell death triggered by excessive DNA damage

Role in Neurodegenerative Diseases

Alzheimer's Disease

Glutamatergic dysfunction is a central feature of [alzheimers](/diseases/alzheimers-disease): [@proteins]

• [amyloid-beta](/proteins/amyloid-beta) toxicity: [amyloid-beta](/proteins/amyloid-beta) oligomers enhance glutamate release, impair astrocytic glutamate reuptake (by downregulating EAAT2/GLT-1), and directly activate extrasynaptic [nmda-receptor](/entities/nmda-receptor) receptor] receptor] receptors], triggering excitotoxic tau] hyperphosphorylation and synaptic loss ([Li et al., 2011](https://doi.org/10.1523/JNEUROSCI.6542-10.2011))
• Synaptic NMDAR loss: Progressive loss of synaptic (GluN2A-containing) NMDARs with preserved or enhanced extrasynaptic (GluN2B-containing) NMDARs shifts signaling from pro-survival to pro-death pathways ([Hardingham & Bading, 2010](https://doi.org/10.1038/nrn2738))
• Memantine: An uncompetitive NMDAR antagonist that preferentially blocks excessive tonic activation while sparing physiological synaptic signaling; the only approved NMDAR-targeting therapy for moderate-to-severe AD ([Lipton, 2006](https://doi.org/10.1038/nrd2098))
• Cholinergic interactions: Glutamatergic and cholinergic systems are intimately interconnected; loss of [acetylcholine](/entities/acetylcholine) modulation exacerbates glutamatergic dysregulation

Parkinson's Disease

In [parkinsons](/diseases/parkinsons-disease): [@neurodegenerativea]

• Loss of dopaminergic [neurons](/entities/neurons) in the [substantia-nigra](/brain-regions/substantia-nigra) leads to disinhibition of subthalamic nucleus glutamatergic output to the [basal-ganglia](/brain-regions/basal-ganglia), creating a hyperglutamatergic state
• Glutamate excitotoxicity contributes to dopaminergic neuronal death through NMDAR-mediated calcium overload
• [alpha-synuclein](/proteins/alpha-synuclein) aggregation impairs glutamate transporter function
• Amantadine, an NMDAR antagonist, is used to manage levodopa-induced dyskinesias
• mGluR5 negative allosteric modulators are under investigation as potential disease-modifying therapies ([Litim et al., 2017](https://doi.org/10.1016/j.neuropharm.2016.10.001))

Amyotrophic Lateral Sclerosis

Glutamate excitotoxicity is strongly implicated in [als](/diseases/amyotrophic-lateral-sclerosis): [@mechanismsa]

• Motor [neurons](/entities/neurons) are particularly vulnerable to excitotoxicity due to high GluA2-lacking (Ca²⁺-permeable) AMPA receptor expression
• EAAT2 (GLT-1) expression is reduced in the spinal cord and motor [cortex](/brain-regions/cortex) of ALS patients, impairing glutamate clearance ([Rothstein et al., 1995](https://doi.org/10.1002/ana.410380314))
• Riluzole: The first FDA-approved ALS drug, acts primarily by inhibiting presynaptic glutamate release and is thought to extend survival by 2–3 months ([Bensimon et al., 1994](https://doi.org/10.1056/NEJM199403033300901))
• [c9orf72](/genes/c9orf72) repeat expansions lead to glutamate receptor dysregulation
• [sod1-protein](/proteins/sod1-protein) mutations increase astrocytic glutamate release and reduce EAAT2 expression

Huntington's Disease

In [huntington-pathway](/mechanisms/huntington-pathway): [@ncbi]

• Medium spiny [neurons](/entities/neurons) in the striatum are selectively vulnerable to excitotoxicity
• Mutant [huntingtin](/proteins/huntingtin) protein sensitizes [nmda-receptor](/entities/nmda-receptor) receptor] receptors (particularly GluN2B-containing receptors) to glutamate, lowering the threshold for excitotoxic damage ([Zeron et al., 2002](https://doi.org/10.1038/nn734))
• Impaired astrocytic glutamate uptake through reduced EAAT2 expression
• Corticostriatal glutamatergic projections become dysfunctional, contributing to aberrant glutamate release
• Mitochondrial dysfunction amplifies vulnerability to excitotoxicity

Multiple Sclerosis

Glutamate excitotoxicity contributes to neurodegeneration in [MS]: [@uniprot]

• Activated immune cells ([microglia](/cell-types/microglia)/entities/microglia** | [astrocytes](/cell-types/astrocytes) | Responsible for ~90% of forebrain glutamate uptake |

| EAAT3 (EAAC1) | [neurons](/entities/neurons) (postsynaptic) | Neuronal glutamate/cysteine uptake | [@ref]
| EAAT4 | Cerebellar Purkinje cells | Limits glutamate spillover |
| EAAT5 | Retina | Photoreceptor glutamate clearance |

EAAT2 dysfunction is implicated in multiple neurodegenerative diseases. Strategies to upregulate EAAT2 expression (e.g., ceftriaxone, GluT-1) are under investigation as potential neuroprotective therapies ([Rothstein et al., 2005](https://doi.org/10.1038/nature03180)).

Therapeutic Strategies Targeting Glutamate

Approved Therapies

• Memantine: Uncompetitive [nmda-receptor](/entities/nmda-receptor) receptor] receptor] receptor] antagonist approved for moderate-to-severe [alzheimers](/diseases/alzheimers-disease) ([Lipton, 2006](https://doi.org/10.1038/nrd2098))
• Riluzole: Presynaptic glutamate release inhibitor approved for [als](/diseases/amyotrophic-lateral-sclerosis) ([Bensimon et al., 1994](https://doi.org/10.1056/NEJM199403033300901))
• Amantadine: Weak NMDAR antagonist used for levodopa-induced dyskinesias in [parkinsons](/diseases/parkinsons-disease)

Investigational Approaches

• GluN2B-selective NMDAR antagonists: Targeting extrasynaptic NMDARs while preserving synaptic signaling
• mGluR5 negative allosteric modulators: Reducing excessive glutamate signaling without completely blocking physiological transmission
• EAAT2 upregulators: Enhancing astrocytic glutamate clearance (e.g., ceftriaxone, LDN/OSU-0212320)
• System Xc⁻ modulators: Targeting the cystine/glutamate antiporter to regulate extracellular glutamate
• Neuroprotective NMDAR modulators: Compounds that selectively block pathological NMDAR activation (e.g., NitroSynapsin, a memantine derivative)
• Kynurenine pathway modulators: Targeting the tryptophan-kynurenine pathway, which produces both neuroprotective (kynurenic acid, an NMDAR antagonist) and neurotoxic (quinolinic acid, an NMDAR agonist) metabolites

Background

The study of Glutamate has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

• Allen Human Brain Atlas: [Glutamate expression search](https://human.brain-map.org/microarray/search/show?search_term=Glutamate)
• Allen Mouse Brain Atlas: [Glutamate search](https://mouse.brain-map.org/search/index.html?query=Glutamate)
• Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
• BrainSpan Developmental Transcriptome: [Glutamate developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Glutamate)
• [Excitotoxicity](/mechanisms/excitotoxicity)
• [nmda-receptor](/entities/nmda-receptor) Receptor
• [AMPA Receptor](/proteins/ampa-receptor)
• [Glutamatergic Signaling](/genes/gnal)
• [Excitatory Neurotransmitter](/genes/ran)
• [Alzheimer's Disease[/Alzheimer'[s-disease[/Alzheimer'[s-disease[/Alzheimer'[s-disease[/Alzheimer'[s-disease[/Alzheimer'[s-disease[/Alzheimer'[s-disease[/Alzheimer'[s-disease](/Alzheimer's-disease)

External Links

• [PubMed Search: Glutamate](https://pubmed.ncbi.nlm.nih.gov/?term=Glutamate)
• [Google Scholar Search: Glutamate](https://scholar.google.com/scholar?q=Glutamate)

References

[Meldrum BS, Glutamate as a neurotransmitter in the brain: review of physiology and pathology (2000))

[Unknown, Dong XX, Wang Y, Bhatt AB. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009;30(4):379-387. [DOI (2009)](https://doi.org/10.1007/s00401-009-0495-z)

[Danbolt NC, Glutamate uptake (2001))

[Unknown, Bhatt DK, Rojas-Perez E, Bhatt R. Glutamate and excitotoxicity in central nervous system disorders: ionotropic glutamate receptors as a target for neuroprotection. Neuroprotection. 2023;2(1):e46. [DOI (2023)](https://doi.org/10.1002/nep3.46)

[Li S, Hong S, Bhatt DK, et al. Soluble oligomers of, amyloid-beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. J Neurosci. 2011;31(16):6233-6246. [DOI (2011)](https://doi.org/10.1523/JNEUROSCI.6542-10.2011)

[Litim N, Bhatt AB, Bhatt DK. Metabotropic glutamate receptors as therapeutic targets in, parkinsons: an update. Neuropharmacology. 2017;115:166-179. [DOI (2017)](https://doi.org/10.1016/j.neuropharm.2016.10.001)

[Unknown, Rothstein JD, Van Kammen M, Bhatt DK. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol. 1995;38(1):73-84. [DOI (1995)](https://doi.org/10.1002/ana.410380314)

[Unknown, Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330(9):585-591. [DOI (1994)](https://doi.org/10.1056/NEJM199403033300901)

[Zeron MM, Bhatt DK, Bhatt R, et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's Disease. , neurons. 2002;33(6):849-860. [DOI (2002)](https://doi.org/10.1038/nn734)

[Rothstein JD, Patel S, Bhatt DK, et al., β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433(7021):73-77. [DOI (2005)](https://doi.org/10.1038/nature03180)

[Unknown, Zhou Y, Bhatt DK, Bhatt R. Bhatt Bhatt — update on glutamate excitotoxicity molecular mechanisms in neurodegeneration. Acta Pharmacol Sin. 2025. [DOI (2025)](https://doi.org/10.1038/s41401-025-01576-w)

[Nguyen H, Bhatt DK, et al., Multi-omic analysis of glutamate excitotoxicity in primary neuronal cultures. J Neurochem. 2025;169(1):e70110. [DOI (2025)](https://doi.org/10.1111/jnc.70110)

[Unknown, Lewerenz J, Maher P. Chronic glutamate toxicity in neurodegenerative diseases — what is the evidence? Front Neurosci. 2015;9:469. [DOI (2015)](https://doi.org/10.3389/fnins.2015.00469)

Unknown, - [Neurodegenerative Diseases (n.d.)

Unknown, - [Genes Index (n.d.)

Unknown, - [Mechanisms of Neurodegeneration (n.d.)

Unknown, - [Proteins Index## See Also (n.d.)

Unknown, - [Neurodegenerative Diseases (n.d.)

Unknown, - [Mechanisms Index## External Links (n.d.)

-, NCBI Gene (n.d.)

-, UniProt (n.d.)

Unknown, - (n.d.)

Pathway Diagram

The following diagram shows the key molecular relationships involving glutamate discovered through SciDEX knowledge graph analysis:

Pathway Diagram

The following diagram shows the key molecular relationships involving glutamate discovered through SciDEX knowledge graph analysis: